Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

泰毕安 - NMPA Drug Approval Details

Approvals/NMPA/Idarucizumab Injection

Approved

生物制品

Idarucizumab Injection

Boehringer Ingelheim International GmbH🇨🇳 National Medical Products Administration

Approval Date: Dec 22, 2022
Approval ID: 1xpZwrDCZgw
Company: Boehringer Ingelheim International GmbH
Type: 生物制品

Approval Details

Approval Id: 1xpZwrDCZgw
Approval Number: 国药准字SJ20180012
Generic Name: 依达赛珠单抗注射液
Generic Name En: Idarucizumab Injection
Trade Name: 泰毕安
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 2.5g/50mL
Reg Date: 2022-12-22
Expired Date: 2027-12-21
Company Name: Boehringer Ingelheim International GmbH
Production Company Name: Boehringer Ingelheim Pharma GmbH & Co. KG
Company Detail Path: /organization/b14d523e0e13638f/boehringer-ingelheim-international-gmbh
Production Company Detail Path: /organization/b3aed260137c33c0/boehringer-ingelheim-pharma-gmbh-and-co-kg

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Dec 22, 2022

Approval ID

1xpZwrDCZgw

Type

生物制品

Back to NMPA Approvals